Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma \textit{in vitro} and \textit{in vivo}

Ying Zhao\textsuperscript{1*}, Yu Zhang\textsuperscript{2*}, Milad Vazirinejad Mehdiabad\textsuperscript{2}, Ke Zhou\textsuperscript{2}, Yuyuan Chen\textsuperscript{2}, Lei Li\textsuperscript{2}, Jun Guo\textsuperscript{2*}, Chuanrui Xu\textsuperscript{2*}

\textsuperscript{1} Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, \textsuperscript{2} School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

\* These authors contributed equally to this work. xcr@hust.edu.cn (CX); 1270079810@qq.com (JG)

Abstract

Hepatocellular carcinoma (HCC) is one of the most malignant cancers and the treatment options for this disease are limited and generally not effective. ROCK has been reported to be highly expressed in many cancer types and its inhibitor Fasudil has shown anti-cancer potential. However, its high toxicity and low solubility restrict its clinical application. Here, we report that Fasudil is effective against HCC and that a liposomal formulation (Lip-Fasudil) can enhance the anti-tumor effects of this drug both \textit{in vitro} and \textit{in vivo}. \textit{In vitro}, Fasudil inhibited HCC cell growth with IC\textsubscript{50} values of 0.025–0.04 \textmu g/\textmu L, with Lip-Fasudil showing slightly improved cytotoxicity with IC\textsubscript{50} values of 0.02–0.025 \textmu g/\textmu L. Cellular mechanistic analysis indicated that Fasudil induced cell cycle arrest at the G2/M phase and that Lip-Fasudil enhanced this effect. Intriguingly, no apoptosis was detected in Fasudil- or Lip-Fasudil-treated HCC cells. \textit{In vivo}, Fasudil inhibited the growth of HCC xenografts by 23% in nude mice. However, Lip-fasudil exerted anti-tumor effects (57% tumor inhibition) that were superior to those of Fasudil and similar to those of Topotecan (66%). In addition, Lip-fasudil resulted in an increased distribution of Fasudil in tumor tissues but a reduced distribution in normal organs. In conclusion, our results proved that Fasudil has the potential to be used for HCC treatment and that a liposomal formulation (Lip-Fasudil) could enhance anti-tumor efficacy and reduce systemic toxicity.

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and one of the most important lethal malignancies worldwide \cite{1, 2}. In China, the incidence of HCC has been increasing continually \cite{3} and the 5-year survival rate has been less than 15\% in the past decade \cite{4, 5}. Currently, optional treatments for liver cancer are very limited and the prognosis is generally unsatisfactory \cite{6–8}. Sorafenib is the only targeted drug approved for the treatment of unresectable liver cancer at present. However, it can only improve the survival of HCC
patients by 2–3 months [9, 10]. Therefore, exploring novel drugs is an urgent need for HCC treatment.

ROCK kinase inhibitors have been widely studied for many types of diseases, and in the 1990s, one such agent, Fasudil, was shown to increase both cerebral blood flow and glucose metabolism. Subsequently, it was approved for the prevention of post-operative cerebral vasospasm and the treatment of subarachnoid hemorrhage in Japan [11–13]. In addition, Fasudil improves p53-mediated apoptosis in human HCC cells [14]. Currently, it is mainly used clinically for the treatment of hypertension, coronary vasospasm, atherosclerosis, pulmonary hypertension, aortic sclerosis, heart failure-related vascular resistance, contraction, cerebral arterial spasm, ischemic stroke, and kidney transplant [13, 15]. However, in 2006, Han et al. proved that Fasudil could inhibit tumor progression using three independent animal models [16]. This result provided a good foundation for the study of Fasudil as an anticancer drug. Further, in 2009, Yang et al. confirmed that Fasudil could inhibit the migration of 95-D lung cancer cells [17]. In addition, they proved that it could suppress tumor growth by inhibiting Rho/Rho kinase signaling, resulting in the downregulation of ABCE1, which regulates the migration of 95-D cells. In 2013, Peng et al. also confirmed that Fasudil could inhibit proliferation after abdominal aortic aneurysm and maintain tumors at their initial size [18]. The mechanism underlying the anti-tumor effect was attributed to damage to the tumor cell membrane. This damage might lead to the infiltration of macrophages along with the angiogenesis. Together, these results suggest that Fasudil has potential for the treatment of different cancers.

However, the anti-tumor effect of Fasudil on HCC had not been fully evaluated. In addition, since Fasudil can act on normal tissues including vasculature and the heart [19–21], its distribution in tumor tissues needs to be improved to reduce side effects and improve its efficacy. In this study, we prepared a liposomal preparation of this drug (Lip-Fasudil) to enhance its distribution in tumor tissues through the EPR effect (enhanced permeability and retention). Then, we examined its cytotoxicity and anti-tumor mechanism in HCC cells, as well as its anti-tumor effect in HCC mouse models.

**Materials and methods**

**Materials**

Fasudil, cholesterol (Chol), L-glutamate, and Sepharose CL-4B chromatography media were purchased from Sigma-Aldrich Chemical Co (St. Louis, MO, USA). DMEM high glucose medium was bought from Hyclone of Thermo Scientific (IL, USA). Trypsin was purchased from Beyotime Institute of Biotechnology (Beijing, China). 1, 2-dioleoyl-3-trimethylammonium-Propane (Chloride Salt) (DOTAP) and monomethoxy polyethylene glycol 2000-distearoyl phosphatidyl-ethanolamine (mPEG-DSPE) were purchased from Avanti Polar Lipid (Alabaster, AL, USA). PD-10 desalting columns were purchased from GE Healthcare Biosciences (PA, USA). All reagents and solvents were of analytical or HPLC grade and were used without further purification.

**Preparation of Fasudil liposomes**

The cationic liposomes were prepared by the thin film hydration and polycarbonate membrane extrusion method according to the literature [22, 23]. DOTAP/Chol/mPEG-DSPE was used at a molar ratio of 40:55:5, respectively. Fasudil was remote loaded into the liposomes by a transmembrane pH gradient. Briefly, the total lipids (85 mg) were dissolved in CHCl3 and dried to a thin film by rotary evaporation followed by further drying under a vacuum at 40 °C. The lipid film was then hydrated with 2 mL (NH4)2SO4 (250 mM) for 30 min at 60 °C [24]. The resultant multilamellar vesicles were extruded five times through 0.2-μm pore-size
polycarbonate membranes and five times through 0.1-μm pore-size polycarbonate membranes using a Lipex Extruder (Northern Lipids Inc., Canada) driven by pressurized nitrogen at 60 °C to produce homogeneous unilamellar vesicles. The residual (NH₄)₂SO₄ was removed with phosphate-buffered saline (PBS, pH 7.4) by size-exclusion chromatography on a PD-10 column. Fasudil (Sigma Chemical Co., St Louis, MO, USA) was loaded into the liposomes at a phospholipid:Fasudil ratio of 1:0.4 (w/w) and incubated for 1 h at 65 °C. Free Fasudil was separated from Lip-Fasudil by size exclusion chromatography on a Sepharose CL-4B column equilibrated with 25 mM HEPES and 140 mM NaCl (HEPES buffer, pH 7.4) [25, 26].

Size and zeta potential
The particle size and zeta potential of the liposomes were measured by Zeta PALS (Zeta Potential Analyzer, Brookhaven Instruments Corporation, Austin, TX) according to the manufacturer’s instructions. All measurements were carried out at room temperature. Each parameter was measured three times, and average values and standard deviations were calculated.

Cell culture
HepG2, Huh7, Hep3B, and SMMC-7721 cells were all from the China Center for Type Culture Collection at Wuhan University (Wuhan, China). These cells were cultured with high glucose DMEM medium supplemented with penicillin, streptomycin and 10% FBS in 37 °C and 5% CO₂ incubators. M-plasmodia (San Diego, CA, USA) at a concentration of 2.5 μg/mL was used to prevent possible mycoplasma infections.

Mice
Female BALB/c nude mice (6–8 weeks of age, 16–18 g) and female FVB/N mice (6–8 weeks of age, 18–20 g) were obtained from Huafukang Technology Corporation (Beijing, China) and kept in filter-topped cages with standard rodent chow and water available ad libitum and a 12-h light/dark cycle. The experiments were performed according to national regulations and approved by the Animal Experiments Ethical Committee of Huazhong University of Science and Technology.

Cytotoxicity
The cytotoxic effect of Lip-Fasudil and free Fasudil against the HCC cells was measured using a Cell Counting Kit-8 kit (CCK-8 kit, Dojindo laboratories, Kumamoto, Japan). HepG2, Huh7, Hep3B, and SMMC-7721 cells were separately seeded into 96-well plates at a density of 5 × 10³ cells/well. After 24 h, cells were treated with Lip-Fasudil and free Fasudil. Cells were further incubated for 24 h and the proportion of viable cells was measured calorimetrically according to the user’s manual. Cell viability within each group was expressed as a percentage of the viability of control cells.

Cell apoptosis analysis
For cell apoptosis analysis by FACS, HCC cells were seeded in DMEM with 10% FBS in 6-well plates (1.5 × 10⁵ cells per well) and allowed to attach overnight. The medium was then changed to fresh DMEM with 10% FBS and cells were treated with PBS (control), free Fasudil (0.02 μg/μL), or Lip-Fasudil (0.02 or 0.03 μg/μL). At the end of treatment for 24 h, cells were harvested in PBS and stained with the Annexin V-FITC Apoptosis Detection kit I (BD Pharmingen TM, San Diego, CA) according to the manufacturer’s instructions. They were then analyzed within
1 h by flow cytometry using a FACS array apparatus (BD Biosciences) with Cell Quest (BD Biosciences) and Mod Fit LT (Verify software, Topsham, MN) software.

**Cell cycle analysis**

For cell cycle analysis, HCC cells were seeded in DMEM with 10% FBS in 6-well plates (1.5 × 10⁵ cells per well) and allowed to attach overnight. The medium was then changed to fresh DMEM with 10% FBS and cells were treated with PBS (control), free Fasudil (0.02 μg/μL), or Lip-Fasudil (0.02 or 0.03 μg/μL) for 24 h. Next, cells were digested with trypsin and collected with the suspension. After fixation with 70% ethanol, cells were incubated with 0.5 mg/mL RNase and 0.025 mg/mL propidium iodide for 30 min. For each sample, 5 × 10⁴ cells were detected by flow cytometry (CytomicsTM FC 500, Beckman Coulter, USA) and the results were analyzed using software FlowJo 7.6 (FlowJo, USA).

**Western blot analysis**

For western blot analysis, HCC cells were seeded in DMEM with 10% FBS in 6-well plates (1.5 × 10⁵ cells per well) and allowed to attach overnight. The medium was then changed to fresh DMEM with 10% FBS and cells were treated with PBS (control), free Fasudil (0.02 μg/μL), or Lip-Fasudil (0.02 or 0.03 μg/μL) for 24 h. Next, cells were lysed in Cell Lysis Reagent (Sigma-Aldrich, MA, USA) for 30 min on ice, and the supernatant was collected after centrifugation at 12,000 g. Cell lysates were separated on a 10% acrylamide gel and transferred to a PVDF membrane. Membranes were blocked for 1 h in 5% skim milk and then incubated with primary antibody overnight. Membranes were washed in TBST (PBS with 0.1% tween-20) three times and then incubated for 1 h with secondary antibody. Then, the membranes were washed four times and developed by an enhanced chemiluminescence system according to the manufacturer’s instructions (Perkin Elmer, Waltham, MA). The antibodies used for Western blotting is listed in Table 1.

**Xenograft mouse model**

For subcutaneous implantation, 4 × 10⁶ Hep3B cells were injected per nude mouse. After implantation, tumor growth was observed every other day and tumor volumes were calculated as \( V = 0.52 \times a \times b^2 \), with “a” representing the long diameter and “b” the short diameter. At a tumor volume of ~100 mm³, liposome or free drugs were injected as a multiple intravenous bolus via intraperitoneal injection at a dose of (30 mg/kg separately) every other day for a total of 10 times. The tumor sizes were measured every 3 days and any animal death was recorded.

**Tissue distribution**

Mouse stomach, hearts, livers, spleens, kidneys and tumor tissues were collected at 0.25, 1, 3, and 6 h after injection. Tissues of 0.1 g were homogenized with 500 μL saline and then centrifuged (Eppendorf5415D, 12,000 g, 15 min) at 4 °C to collect the supernatant. Then 200 μL of supernatant was added to 200 μL methyl alcohol and 400 μL DMSO and the mixture was vortexed for 30 s and centrifuged at 4 °C (12000 × g, 10 min) to separate the Fasudil-containing supernatant from the tissue protein. The absorption of Fasudil standard solutions and samples in tissues were measured by HPLC at an excitation wavelength of 276 nm (High performance liquid chromatograph Waters, American). The concentration of Fasudil in each sample was calculated by using as standard curve determined by a series of Fasudil dilutions.
Hydrodynamic injection, free Fasudil, and Lip-Fasudil treatment

For hydrodynamic injections, 25 μg of the plasmids carrying the genes (Akt and RAS in pT3-EF1a) with a sleeping beauty transposase (pCMV-SB) at a ratio of 25 μg: 25 μg: 5 μg were diluted in 2 mL saline (0.9% NaCl) for each mouse. Saline solution was filtered through a 0.22-μm filter and then injected into the lateral tail vein of 6–8-week-old FVB mice over 5–7 s. After 1 week post-injection, liposomal or free drugs were injected via i.p. at a dose of 50 mg/kg for 3 weeks. All plasmids were gifts from Dr. Xin Chen (University of California at San Francisco). All animal experiments were approved by the Animal Care and Use Committee at Huazhong University of Science and Technology.

Immunohistochemistry

Livers were fixed in 4% paraformaldehyde and embedded in paraffin. For immunohistochemistry, deparaffinized sections were incubated in 3% H₂O₂ dissolved in 1× phosphate-buffered saline (PBS) for 30 min to quench the endogenous peroxidase. For antigen retrieval, slides were microwaved in 10 mM citrate buffer (pH 6.0) for 10 min. Subsequently, slides were incubated with primary antibodies overnight at 4 °C. All primary antibodies used in the present investigation were selected among those that were previously validated by the manufacturers for immunohistochemistry. The immunoreactivity was visualized with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). The specificity of primary antibody reactivity was confirmed by either omitting the primary antibody in the immunohistochemical procedure or, when available, by incubating the primary antibody for 2 h at room temperature with its specific blocking peptide in a 1:2 dilution, before adding the primary antibody to the slides. Slides were counterstained with Mayer’s hematoxylin. The antibodies used for IHC is listed in Table 2.

Table 1. Primary antibodies used for western blotting.

| Name         | Mono/Poly | Host Species | Source   | Catalogue Number | Dilution |
|--------------|-----------|--------------|----------|------------------|----------|
| Cyclin A2    | Poly      | Rabbit       | Proteintech | 18202-1-AP       | 1:1000   |
| Cyclin B1    | Poly      | Rabbit       | Proteintech | 55004-1-AP       | 1:1000   |
| Cyclin E1    | Poly      | Rabbit       | Proteintech | 11554-1-AP       | 1:1000   |
| Cyclin D1    | Mono      | Mouse        | Proteintech | 60186-1-lg       | 1:1000   |
| Bcl2         | Mono      | Rabbit       | CST      | 3498             | 1:1000   |
| Bax          | Poly      | Rabbit       | CST      | 2772             | 1:1000   |
| β-actin      | Mono      | Rabbit       | CST      | 4970             | 1:1000   |
| AKT          | Mono      | Rabbit       | CST      | 4691             | 1:1000   |
| p-AKT(473)   | Mono      | Rabbit       | CST      | 4060             | 1:1000   |
| ERK(1/2)     | Mono      | Rabbit       | CST      | 4695             | 1:1000   |
| p-ERK(1/2)(Thr202/Tyr204) | Mono | Rabbit | CST | 4370             | 1:1000   |
| GAPDH        | Poly      | Rabbit       | Proteintech | 10494-1-AP       | 1:1000   |

Table 2. Primary antibodies used for immunohistochemistry.

| Name         | Mono/Poly | Host Species | Source   | Catalogue Number | Dilution |
|--------------|-----------|--------------|----------|------------------|----------|
| p-AKT(473)   | Mono      | Rabbit       | CST      | 4060             | 1:200    |
| HA           | Poly      | Rabbit       | Proteintech | 51064-2-AP       | 1:100    |
| N-Ras        | Poly      | Rabbit       | Proteintech | 10724-1-AP       | 1:200    |
| Ki67         | Poly      | Rabbit       | Abcam    | Ab15580          | 1:200    |

https://doi.org/10.1371/journal.pone.0223232.t001

https://doi.org/10.1371/journal.pone.0223232.t002
Humane endpoints

All 12 nude mice and nine FVB mice were monitored every day during the study. Monitoring included weight, activity, sizes of tumor (nude mice), or degree of abdominal swelling (FVB mice). All control mice and most treated mice were euthanized by cervical dislocation immediately when the control group mice had a body condition score of 2 or less and a low activity with large tumors (nude mice) or a noticeable swelling abdominal mass (FVB mice). In addition, the remaining treated mice were used for survival analysis and were sacrificed at specific days after control mice were euthanized. The weight, liver weight, tumor size, and date of sacrifice were recorded.

Statistical analysis

All in vitro experiments were repeated three times and in vivo experiments were repeated two times. All statistical analyses were performed using Graph Pad Prism 5.0 software. The differences between groups were compared using a Student’s t-test and data were expressed as the mean ± SD. Values of P < 0.05 were considered significant.

Results

Preparation and characterization of Lip-Fasudil

Lip-Fasudil was prepared according to the methods mentioned in the materials and methods. Examination by transmission electron microscopy showed that the liposomes were round and dispersed well in water solution (Fig 1A). As determined by dynamic light scattering, the average particle size of Lip-Fasudil was 131.2 nm (Fig 1B) and the zeta potential was 38.42 mV (Fig 1C). The polydispersity index was 0.124, suggesting an even distribution of particle sizes (Fig 1C). These results indicated the Lip-Fasudil was prepared with uniform shapes and sizes.

Both Fasudil and Lip-Fasudil exert cytotoxic effects against HCC cells

To examine the cytotoxicity of Lip-Fasudil and free Fasudil using four HCC cell lines, we examined their activities at different concentrations (0, 0.01, 0.02, 0.03, 0.04, and 0.05 μg/μL) for 24 h. In HepG2, Huh7, Hep3B, and SMMC-7721 cells, IC50 values of free Fasudil were 0.03, 0.04, 0.03, and 0.025 μg/μL, respectively, whereas those of Lip-Fasudil were approximately 0.02, 0.025, 0.02, and 0.02 μg/μL, respectively (Fig 2). Treatment with free Fasudil for 24 h significantly inhibited the growth of all four HCC cell lines. Likewise, Lip-Fasudil showed comparable cytotoxicity with free Fasudil after 24 h of treatment (Fig 2). Therefore, both Fasudil and Lip-Fasudil showed anti-tumor activity against HCC cells and that of Lip-Fasudil was higher than that of free Fasudil. In addition, increasing the dose of Fasudil or Lip-Fasudil was found to augment cell death, suggesting that the cytotoxicity of Fasudil and Lip-Fasudil was dose-dependent in these cell lines.

Fasudil and Lip-Fasudil kill HCC cells independent of apoptosis

To investigate the anti-tumor mechanism underlying the effects of Fasudil and Lip-Fasudil on HCC cells, we evaluated their impact on cell apoptosis and cell cycle progression. Cells were collected after 24 h of drug treatment and flow cytometry (FACS) was performed. In HepG2, Huh7, Hep3B, and SMMC-7721 cells, free Fasudil induced apoptosis in only 6.20%, 17.60%, 1.99%, and 0.83% cells, respectively. In comparison, 0.02 μg/μL Lip-Fasudil resulted in apoptosis in 5.30%, 27.60%, 7.34%, and 0.80% cells, respectively (Fig 3). These results showed that in HCC cells, the induction of cellular apoptosis was not a major mechanism through which both free Fasudil and Lip-Fasudil inhibited HCC growth.
However, we observed visible morphological changes in cells. FACS results showed that both Fasudil and Lip-Fasudil increased non-apoptotic cell death in HepG2 cells. Free Fasudil induced non-apoptotic death in approximately 5.3% of cells, whereas 0.02 and 0.03 μg/μL Lip-Fasudil resulted in non-apoptotic death in 18.9% and 25.5% of cells (Fig 3A). These results suggested that Lip-Fasudil increases non-apoptotic cell death in a dose-dependent manner. Similar results were observed with Huh7, Hep3B, and SMMC-7721 cells. Free Fasudil induced non-apoptotic cell death in approximately 21.80%, 16.20%, and 5.89% of Huh7, Hep3B, and SMMC-7721 cells, respectively. In comparison, 0.02 μg/μL Lip-Fasudil resulted in rates of 26.4%, 21.60%, and 5.47%, and 0.03 μg/μL Lip-Fasudil induced non-apoptotic death in 31.70%, 31.00%, and 5.64% of cells, respectively (Fig 3B, 3C and 3D). In those cells, both free

Fig 1. Preparation and characterization of Lip-Fasudil. (A) Morphology of Lip-Fasudil, as detected by TEM; (B) size distribution of Lip-Fasudil; (C) zeta potential of Lip-Fasudil. Experiments were repeated three times and data are expressed as the mean ± SD (n = 3). Scale bar = 100 nm.

https://doi.org/10.1371/journal.pone.0223232.g001

Fig 2. Cytotoxic effects of Lip-Fasudil and free Fasudil against four hepatocellular carcinoma (HCC) cell lines. Cells were treated with free Fasudil and Lip-Fasudil at concentrations of 0, 0.01, 0.02, 0.03, 0.04, and 0.05 μg/μL for 24 h. A no treatment group was used as a negative control. Data from the groups were then compared by one-way ANOVA with a Dunnett’s post-test. Data are expressed as the mean ± SD (n = 3). *p < 0.05 and **p < 0.01.

https://doi.org/10.1371/journal.pone.0223232.g002
Fasudil and Lip-Fasudil did not increase the proportion of apoptotic cells significantly, but profoundly increased the incidence of non-apoptotic cell death. Taken together, these results demonstrated that Fasudil exerts anti-tumor activity by increasing non-apoptotic cell death and that Lip-Fasudil shows enhanced anti-tumor effects, as compared to Fasudil, by promoting this activity.

**Fasudil and Lip-Fasudil induce non-apoptotic programmed cell death by blocking cell cycle progression**

To investigate how Fasudil or Lip-Fasudil induced non-apoptotic programmed cell death in HCC cells, we performed flow cytometric analysis to examine cell cycle progression after drug treatment. Flow cytometry results showed that free Fasudil resulted in an increased ratio of G2/M phase HepG2 cells (18.90%) and that Lip-Fasudil treatment led to the accumulation of cells in G2/M phase (21.13%) compared to that with free Fasudil. More importantly, with increasing concentrations of Lip-Fasudil, the ratio of HepG2 cells in G2/M phase (30.30%) was also increased (Fig 4A). The same effect was observed in Huh7, Hep3B, and SMMC-7721 cells. In these cells, proportions of cells in the G2/M phase were 15.13%, 16.41%, and 13.12%, respectively. Further, after treatment with 0.02 μg/μL free Fasudil, the proportions of cells in the G2/M phase were increased to 18.14%, 30.56%, and 24.05%, respectively. In contrast,
Lip-Fasudil treatment increased cells in the G2/M phase to 22.09%, 33.13%, and 44.02%, respectively. Further, 0.03 μg/μL Lip-Fasudil treatment increased these proportions to 24.46%, 65.31%, and 69.97%, respectively (Fig 4B, 4C and 4D). These results suggested that Fasudil blocks cell cycle progression at G2/M phase in HCC cells and then induces non-apoptotic cell death.

To further confirm this conclusion, we detected the expression of cell cycle- and apoptosis-related proteins in drug-treated cells by western blotting. The result showed that Fasudil and Lip-Fasudil could markedly reduce ROCK2 expression (Fig 5). Moreover, in HepG2, Huh7, Hep3B, and SMMC-7721 cells, expression levels of the apoptosis-related protein BCL2 did not change significantly after the administration of Fasudil and Lip-Fasudil (Fig 5); however, the expression of Bax was marginally increased in HepG2 cells (Fig 5A). In addition, cyclin D1 was downregulated upon Fasudil and Lip-Fasudil treatment. Cyclin A2 and cyclin B1 also exhibited higher expression levels due to cell cycle blockade in the G2/M phase (Fig 5). These results were consistent with the flow cytometric results indicating that Fasudil could induce cell cycle arrest at the G2/M phase. In addition, cell cycle arrest caused by Lip-Fasudil was more remarkable than that with Fasudil.

**Lip-Fasudil shows enhanced anti-tumor effects against tumor xenografts**

The anti-tumor efficacies of Fasudil and Lip-Fasudil were further evaluated using a Hep3B xenograft tumor model. Fasudil and Lip-Fasudil were administrated by intraperitoneal injection when the subcutaneous tumor grew to ~100 mm³. The injection was conducted every

---

0.02 μg/μL Lip-Fasudil treatment increased cells in the G2/M phase to 22.09%, 33.13%, and 44.02%, respectively. Further, 0.03 μg/μL Lip-Fasudil treatment increased these proportions to 24.46%, 65.31%, and 69.97%, respectively (Fig 4B, 4C and 4D). These results suggested that Fasudil blocks cell cycle progression at G2/M phase in HCC cells and then induces non-apoptotic cell death.

To further confirm this conclusion, we detected the expression of cell cycle- and apoptosis-related proteins in drug-treated cells by western blotting. The result showed that Fasudil and Lip-Fasudil could markedly reduce ROCK2 expression (Fig 5). Moreover, in HepG2, Huh7, Hep3B, and SMMC-7721 cells, expression levels of the apoptosis-related protein BCL2 did not change significantly after the administration of Fasudil and Lip-Fasudil (Fig 5); however, the expression of Bax was marginally increased in HepG2 cells (Fig 5A). In addition, cyclin D1 was downregulated upon Fasudil and Lip-Fasudil treatment. Cyclin A2 and cyclin B1 also exhibited higher expression levels due to cell cycle blockade in the G2/M phase (Fig 5). These results were consistent with the flow cytometric results indicating that Fasudil could induce cell cycle arrest at the G2/M phase. In addition, cell cycle arrest caused by Lip-Fasudil was more remarkable than that with Fasudil.

**Lip-Fasudil shows enhanced anti-tumor effects against tumor xenografts**

The anti-tumor efficacies of Fasudil and Lip-Fasudil were further evaluated using a Hep3B xenograft tumor model. Fasudil and Lip-Fasudil were administrated by intraperitoneal injection when the subcutaneous tumor grew to ~100 mm³. The injection was conducted every
other day for a total of 10 doses. On the 24th day after the first injection, the mice were sacrificed, and tumors were collected for volume determinations. Compared to that in the saline group (0.62 g, 1450 mm$^3$), free Fasudil treatment (0.43g, 1120 mm$^3$) inhibited tumor growth by 23% (Fig 6A and 6B). Lip-Fasudil (0.36g, 626 mm$^3$, 57%) showed an enhanced anti-tumor effect compared to that with free Fasudil, but its effect was decreased compared to that of Topotecan (0.16g, 488 mm$^3$, 66%) (Fig 6A and 6B). Body weight examination also showed that the tumor burden in Lip-Fasudil-treated mice was much less than that in free Fasudil-treated mice (Fig 6C). Tumor growth curves showed that the anti-tumor effects of free Fasudil and Lip-Fasudil were due to continuous growth inhibition induced by these formulations (Fig 6D). Of note, Topotecan resulted in significantly increased levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, indicating liver injury in mice (Fig 6E). In comparison, free-Fasudil-treated mice had lower AST and ALT levels than those treated with Topotecan, indicating diminished hepatic toxicity. Interestingly, Lip-Fasudil resulted in a further reduction in hepatic toxicity. Collectively, these data suggested that Fasudil exerts anti-tumor effects in a xenograft tumor model and that Lip-Fasudil has enhanced anti-tumor effects and reduced systemic toxicity.

Lip-Fasudil increases the accumulation of Fasudil in tumor tissue

According to the aforementioned results, we inferred that the liposomal preparation (Lip-Fasudil) could increase the distribution of Fasudil in tumor tissues. To compare the distribution of free Fasudil and Lip-Fasudil in mouse tissues, we injected tumor-bearing mice with each preparation and then examined their distribution. Compared to that with free Fasudil, Lip-Fasudil significantly increased the amount of Fasudil in the mouse liver, spleen, stomach, and kidney at 0.25 h after injection (Fig 7A–7E). Further, the amount of free Fasudil in tumor
tissue was significantly lower than that of Lip-Fasudil at 0.25, 1, and 3 h after injection (Fig 7F). These results indicated that Lip-Fasudil could increase the accumulation of Fasudil in tumor tissues through EPR effects.

Lip-Fasudil improves the anti-tumor effect of free Fasudil in AKT/Ras-induced HCC model

We then explored the therapeutic potential of Fasudil and Lip-Fasudil in primary mouse HCC models. An Akt/Ras-induced primary HCC mouse model was established by the hydrodynamic injection of plasmids carrying the Akt and Ras oncogenes into mice, as previously described [27]. One week after Akt/Ras injection, free Fasudil and Lip-Fasudil were injected (i. p) at a dose of 50 mg/kg every day for 3 weeks. At 4.2 weeks after hydrodynamic injection, all mice were sacrificed. Many nodules were observed on the liver in the control group. However, fewer nodules were observed in Fasudil and Lip-Fasudil group mice. Interestingly, the enhanced anti-tumor effect of Lip-Fasudil was confirmed by observed decreases in liver and body weight (Fig 8A, 8B and 8C). Survival curves also indicated that Lip-Fasudil could prolong the life of HCC mice by more than 4 weeks (Fig 8D). In addition, expression levels of p-AKT (S473), AKT, p-ERK, and ERK in different groups were determined by western blotting and immunohistochemical staining. The results showed that both AKT (with a HA tag) and Ras were expressed in AKT/Ras-injected mouse liver tissues (Fig 8E and 8F). However, Fasudil and Lip-Fasudil reduced the levels of AKT, p-AKT, Erk, and p-Erk, downstream effectors of Ras signaling, concomitant with reduced tumor growth. Moreover, the decrease in Ki67 staining in treated liver tissues demonstrated that Fasudil could suppress tumor cell proliferation and that Lip-Fasudil could further enhance this effect (Fig 8F). Taken together, these results showed that Fasudil is effective against HCC and that Lip-Fasudil can enhance its anti-tumor effects by improving its distribution in tumor tissues.
Discussion

HCC is a serious threat to human health, and the incidence of this disease has been increasing for decades. However, drugs approved for HCC treatment are extremely limited. In this study, we explored the anti-tumor activity of Fasudil in HCC cells and a mouse model. Our results clearly demonstrated that it has anti-tumor activity for HCC \textit{in vivo} and \textit{in vitro}. Thus, our study provides evidence for the potential application of Fasudil in HCC treatment.

We further demonstrated the anti-tumor effect of Fasudil in HCC cells. \textit{In vitro}, both Fasudil and Lip-Fasudil could inhibit the growth of HCC cells by blocking cell cycle progression and promoting non-apoptotic programmed cell death. However, neither free Fasudil nor Lip-

---

**Fig 7. Distribution of free Fasudil and Lip-Fasudil in xenograft mouse model.** Mice were injected (i.p) with free Fasudil (30 mg/kg) or liposomal Fasudil (30 mg/kg), and tissues were collected at 0.25, 1, 3, and 6 h post-injection. Organs (A to E) or tumor (F) samples were homogenized and drugs were extracted to analyze the Fasudil content using HPLC. Data are presented as the average ± standard error (n = 3), and the statistical significance level was *p < 0.05, **p < 0.01.

https://doi.org/10.1371/journal.pone.0223232.g007

**Fig 8. Anti-tumor effects of free Fasudil or Lip-Fasudil in hepatocellular carcinoma (HCC) mouse model induced by AKT and N-Ras oncogenes.** Liver gross image (A), liver weight (B), body weight (C) and survival curve (D) of mice that treated with saline, free Fasudil (50 mg/kg) or Lip-Fasudil (50 mg/kg). (E) Protein expression of p-AKT (S473), t-AKT, p-ERK and t-ERK in WT, AKT/Ras saline, AKT/Ras free Fasudil and AKT/Ras Lip-Fasudil liver tissues, GAPDH was used as loading control. (F) Immunohistochemistry analysis of H&E, HA, p-AKT (S473), N-Ras and Ki67 in different groups. Data are presented as average ± standard error (n = 3), and the statistical significance level is *p < 0.05, **p < 0.01 and ***p < 0.001.

https://doi.org/10.1371/journal.pone.0223232.g008
Fasudil induced apoptosis in four HCC cell lines. However, both induced cell cycle arrest in HCC cells and then induced non-apoptotic programmed cell death. The effect of Fasudil on cell cycle progression was possibly due to its inhibition of Rho kinase. The inhibition of Rho kinase blocks actomyosin contractility by dephosphorylation and the activation of myosin light chain phosphatase [28]. Several studies have revealed that the Rho/ROCK pathway plays a crucial role in modulating cell skeleton reorganization via myosin light chain phosphorylation [29]. Hence, Fasudil might block cell cycle progression by inhibiting the formation of spindle bodies during cellular mitosis.

In addition, our study investigated the feasibility of using liposomes to deliver Fasudil and demonstrated that Lip-Fasudil had significantly enhanced anti-tumor effects, compared to those with Fasudil, with reduced systemic cytotoxicity. Since Doxil, the first liposomal pharmaceutical product, was approved by the FDA in 1995, liposomes have been intensively investigated for applications in clinics. Many types of liposomes including PEGylated liposomes (Doxil, Lipo-dox), temperature-sensitive liposomes (ThermoDox), cationic liposomes (Endo-TAG-1), and virosomes (Epaxal and Inflexal V) have been tested clinically or developed for clinical use (at different stages) [30]. Accumulating evidence has demonstrated that liposomal formulations can prolong blood circulation time, vary drug distribution in the body, and thus reduce possible side effects related to the drugs (e.g., cardiotoxicity). However, liposome formulations are not suitable for all drugs and they have some limitations. For example, in comparison with Doxil, ThermoDox resulted in significantly diminished doxorubicin accumulation in mouse tumors 24 h after administration [31]. In this study, we found that liposomes can significantly increase the uptake and accumulation of Fasudil in tumor tissues. Correspondingly, Lip-Fasudil significantly enhanced the anti-tumor effect of Fasudil in xenograft and primary HCC models, even though it showed only slightly higher anti-tumor activity than free-Fasudil in vitro.

Moreover, Lip-Fasudil was found to increase the therapeutic window of Fasudil. In our pilot study, we found that 100 mg/kg Fasudil administrated i.v. caused the death of tumor-bearing mice (data not shown). In contrast, Fasudil at doses lower than 30 mg/kg showed only minor anti-tumor effects (data not shown). Similar results obtained by other groups using Fasudil to treat lung cancer in mice have been reported [16]. These results demonstrate the narrow therapeutic window of Fasudil, which might hinder its clinical application for cancer treatment. However, since Lip-Fasudil reduced the distribution of Fasudil in other normal tissues and hence reduced systemic toxicity, the administrative doses could be escalated when necessary in the clinics. To conclude, our study indicated that Fasudil is effective in inhibiting HCC growth and that Lip-Fasudil can enhance its efficacy and reduce its toxicity. Therefore, liposomal Fasudil holds great potential for use for the treatment of liver cancer.

Supporting information

S1 Minimal Data. Relevant data described in manuscript. (ZIP)

Acknowledgments

This work was financially supported by the National Science Foundation of China (81370058 and 81572723 to Chuanrui Xu, and 81872253 to Lei Li) and Natural Science Foundation of Hubei Province of China (2015CFB611 to Ying Zhao). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Contributions

Conceptualization: Chuanrui Xu.

Investigation: Ying Zhao, Yu Zhang, Milad Vazirinejad Mehdiabad, Ke Zhou, Jun Guo.

Methodology: Yu Zhang, Ke Zhou, Yuyuan Chen.

Project administration: Lei Li, Chuanrui Xu.

Resources: Lei Li, Chuanrui Xu.

Writing – original draft: Yu Zhang, Jun Guo.

Writing – review & editing: Ying Zhao, Lei Li, Chuanrui Xu.

References

1. Parkin D.M., Global cancer statistics in the year 2000. Lancet Oncol, 2001. 2(9): p. 533–43. https://doi.org/10.1016/S1470-2045(01)00486-7 PMID: 11905707

2. Parkin D.M., et al., Estimating the world cancer burden: Globocan 2000. Int J Cancer, 2001. 94(2): p. 153–6. https://doi.org/10.1002/ijc.1440 PMID: 11668491

3. El-Serag H.B. and Mason A.C., Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 1999. 340(10): p. 745–50. https://doi.org/10.1056/NEJM199903113401001 PMID: 10072408

4. El-Serag H.B., Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 2004. 127(S Suppl 1): p. S27–34. https://doi.org/10.1053/j.gastro.2004.09.013 PMID: 15508094

5. Mittal S. and El-Serag H.B., Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol, 2013. 47 Suppl: p. S2–6.

6. Bruix J., et al., Focus on hepatocellular carcinoma. Cancer Cell, 2004. 5(3): p. 215–9. PMID: 15050913

7. Llovet J.M. and Bruix J., Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008. 48 Suppl: p. S20–37.

8. Spangenberg H.C., Thimme R., and Blum H.E., Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2009. 6(7): p. 423–32. https://doi.org/10.1038/nrgastro.2009.86 PMID: 19488072

9. Llovet J.M., et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008. 359(4): p. 378–90. https://doi.org/10.1056/NEJMoa0708857 PMID: 18650514

10. Kane R.C., et al., Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist, 2009. 14(1): p. 95–100. https://doi.org/10.1634/theoncologist.2008-0185 PMID: 19146478

11. Sako K., et al., HA1077, a novel calcium antagonistic antivasospasm drug, increases both cerebral blood flow and glucose metabolism in conscious rats. European journal of pharmacology, 1991. 209(1–2): p. 39–43. https://doi.org/10.1016/0014-2999(91)90088-e PMID: 1914759

12. Takayasu M. and Dacey R.G. Jr., Effects of HA1077, a novel calciumantagonistic spasmylytic agent on intracerebral arterioles of rats. Acta Neurochir (Wien), 1990. 103(1–2): p. 67–70.

13. Shi J. and Wei L., Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol, 2013. 62(4): p. 341–54. https://doi.org/10.1097/FJC.0b013e3182a3718f PMID: 23921309

14. Takeba Y., et al., The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemother Pharmacol, 2012. 69(6): p. 1545–55. https://doi.org/10.1007/s00280-012-1862-6 PMID: 22481618

15. Nakashima S., et al., Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo), 1998. 38(12): p. 805–10; discussion 810–1.

16. Ying H., et al., The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther, 2006. 5(9): p. 2158–64. https://doi.org/10.1158/1535-7183.MCT-05-0440 PMID: 16985048

17. Yang X., et al., The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother, 2010. 64(1): p. 58–62. https://doi.org/10.1016/j.biopharm.2009.08.006 PMID: 19879105
18. Peng C., et al., Inhibition of rho-kinase by fasudil suppresses formation and progression of experimental abdominal aortic aneurysms. PLoS One, 2013. 8(11): p. e80145. https://doi.org/10.1371/journal.pone.0080145 PMID: 24244631

19. Hu L., et al., Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Front Med, 2016. 10(1): p. 61–75. https://doi.org/10.1007/s11684-016-0436-0 PMID: 26969667

20. Wolfrum S., et al., Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol, 2004. 24(10): p. 1842–7. https://doi.org/10.1161/01.ATV.0000142813.33538.82 PMID: 15319269

21. Li Y., et al., Fasudil protects the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: the differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. PLoS One, 2012. 7(10): p. e48115. https://doi.org/10.1371/journal.pone.0048115 PMID: 23118936

22. Pan X.Q., et al., Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 2002. 100(2): p. 594–602. https://doi.org/10.1182/blood.v100.2.594 PMID: 12091353

23. Haran G., et al., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta, 1993. 1151(2): p. 201–15. https://doi.org/10.1016/0005-2736(93)90105-9 PMID: 8373796

24. Ishida T., et al., Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharm, 2002. 232(1–2): p. 59–67. https://doi.org/10.1016/s0378-5173(01)00896-1 PMID: 11790490

25. Takanashi Y., et al., Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats. J Clin Neurosci, 2001. 8(6): p. 557–61. https://doi.org/10.1054/jocn.2001.0998 PMID: 11683605

26. Bartlett G.R., Phosphorus assay in column chromatography. J Biol Chem, 1959. 234(3): p. 466–8. PMID: 13641241

27. Chen X. and Calvisi D.F., Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol, 2014. 184(4): p. 912–923. https://doi.org/10.1016/j.ajpath.2013.12.002 PMID: 24480331

28. Wettenschueck N. and Offermanns S., Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl), 2002. 80(10): p. 629–38.

29. Fukata Y., Amano M., and Kaibuchi K., Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci, 2001. 22(1): p. 32–9. https://doi.org/10.1016/s0165-6147(00)01596-0 PMID: 11165670

30. Chang H.I. and Yeh M.K., Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 7: p. 49–60. https://doi.org/10.2147/IJN.S26766 PMID: 22275822

31. Dromi S., et al., Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res, 2007. 13(9): p. 2722–7. https://doi.org/10.1158/1078-0432.CCR-06-2443 PMID: 17473205